Your browser doesn't support javascript.
Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes.
Hu, Yuxuan; Wang, Yanning; Shao, Taihang; Tang, Wenxi; Hu, Kerong; Zhou, Yujie; Miao, Liyun; Liu, Jing; Wang, Bin; Yu, Wenying.
  • Hu Y; Institute of Pharmaceutical Sciences, China Pharmaceutical University, Nanjing 211198, PR China.
  • Wang Y; Clinical Stem Cell Center, The Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing 210008, PR China.
  • Shao T; Department of Pharmacoeconomics, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, PR China.
  • Tang W; Department of Pharmacoeconomics, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, PR China.
  • Hu K; Department of Infectious Diseases, Huangshi Love&Health Hospital, Huangshi 435000, PR China.
  • Zhou Y; Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, Nanjing 210008, PR China.
  • Miao L; Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, Nanjing 210008, PR China.
  • Liu J; Clinical Laboratory, Nanjing Yuhua Hospital (Yuhua Branch of Nanjing First Hospital), Nanjing 210039, PR China. Electronic address: hb670505@163.com.
  • Wang B; Clinical Stem Cell Center, The Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing 210008, PR China. Electronic address: wangbin022800@126.com.
  • Yu W; Institute of Pharmaceutical Sciences, China Pharmaceutical University, Nanjing 211198, PR China. Electronic address: ywy@cpu.edu.cn.
Vaccine ; 41(18): 3003-3010, 2023 05 02.
Article in English | MEDLINE | ID: covidwho-2296670
ABSTRACT

INTRODUCTION:

Here, we systematically assessed the safety and immunogenicity of the heterologous ChAd/BNT vaccination regimens. MATERIALS AND

METHODS:

We evaluated the immunogenicity by the geometric mean titers ratio (GMTR) of the neutralizing antibody and anti-spike IgG. The safety of heterologous ChAd/BNT vaccination was evaluated using the pooled risk ratios (RRs) calculated by the random-effects model about the adverse events. Our study was registered with PROSPERO, CRD42021265165.

RESULTS:

Eleven studies were included in the analyses. Compared to the homologous ChAd/ChAd vaccination, the heterologous ChAd/BNT vaccination showed significantly higher immunogenicity in terms of the neutralizing antibody and GMTR of anti-spike IgG, but at the same time displayed higher incidence of total adverse reactions, especially for the local adverse reactions. Moreover, heterologous ChAd/BNT vaccination showed similar immunogenicity to the homologous BNT/BNT vaccination (GMTR of neutralizing antibody and anti-spike IgG) and similar safety.

DISCUSSION:

Heterologous ChAd/BNT vaccination showed robust immunogenicity and tolerable safety.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / BNT162 Vaccine Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Reviews Topics: Vaccines Limits: Humans Language: English Journal: Vaccine Year: 2023 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / BNT162 Vaccine Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Reviews Topics: Vaccines Limits: Humans Language: English Journal: Vaccine Year: 2023 Document Type: Article